Human CD38 Regulates B Cell Antigen Receptor Dynamic Organization in Normal and Malignant B Cells

The authors showed that targeting CD38 with an antibody, or removing this molecule with CRISPR/Cas9, inhibited the association of CD19 with the IgM-B cell receptor (BCR), impairing BCR signaling in normal and malignant B cells.